Indapta Therapeutics
Healthcare & Life Sciences
Recent Finacing
Equity
Recent Raise
$22.5M
Indapta Therapeutics develops allogeneic Natural Killer (NK) cell therapies for treating cancer and autoimmune diseases.
Focus Areas
Biotechnology
Clinical-stage
NK cell therapy
Cancer
Autoimmune diseases
Cell therapies
Investors
